Novel Antibiotics for Urinary Tract Infection (UTI): The EAGLE 2 and EAGLE-3 Trials for Uncomplicated UTI, and the CERTAIN-1 Trial for Complicated UTI

Florian Wagenlehner

doi:10.1016/j.euf.2024.07.014

Novel Antibiotics for Urinary Tract Infection (UTI): The EAGLE 2 and EAGLE-3 Trials for Uncomplicated UTI, and the CERTAIN-1 Trial for Complicated UTI

Eur Urol Focus. 2024 Sep;10(5):694-696. doi: 10.1016/j.euf.2024.07.014. Epub 2024 Aug 6.

Author

Florian Wagenlehner¹

Affiliation

¹ Clinic of Urology, Pediatric Urology and Andrology, Justus Liebig University Giessen, Giessen, Germany. Electronic address: florian.wagenlehner@chiru.med.uni-giessen.de.

PMID: 39112136
DOI: 10.1016/j.euf.2024.07.014

Abstract

Two novel antibiotics have been evaluated for the treatment of urinary tract infection (UTI). Gepotidacin was an efficacious first-in-class oral antibiotic in uncomplicated UTI in comparison to nitrofurantoin. Cefepime/taniborbactam was superior to meropenem in complicated UTI and acute pyelonephritis.

MeSH terms

Anti-Bacterial Agents* / therapeutic use
Cefepime / therapeutic use
Cephalosporins / therapeutic use
Humans
Meropenem / therapeutic use
Pyelonephritis / drug therapy
Randomized Controlled Trials as Topic
Urinary Tract Infections* / drug therapy

Substances

Anti-Bacterial Agents
Cephalosporins
Cefepime
Meropenem